ANIFROLUMAB
Information current as at: 1 April 2024
PBAC meeting date: July 2022
Submission Details
- Brand name:
-
- Saphnelo®
- Pharmaceutical company:
- AstraZeneca Pty Ltd
- Condition/indication:
(therapeutic use) -
- Systemic lupus erythematosus
- PBAC Submission type:
- New PBS listing (Category 1)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – July 2022
- Related medicines:
- --
Progress Details
-
Submission received for: - July 2022 PBAC meeting
-
Opportunity for consumer comment: - Open 30/03/2022 and close 25/05/2022 (see PBS Website)
-
PBAC meeting: - Held on 06/07/2022
-
PBAC outcome published: - Not Recommended (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a525
Page last updated: 04 April 2024